Displaying 1–25 of 3996 results for
Indian Regulators have warned both Indian and foreign pharmaceutical companies to beware of a scam involving people posing as U.S. FDA officials, demanding cash payments for approvals.
WuXi PharmaTech recently announced it received an honorable mention from the International Society for Pharmaceutical Engineering's (ISPE) 2014 Facility of the Year Awards committee for the company's recently completed cGMP cell-culture-based biologics production facility in Wuxi, China.
Activist investor Bill Ackman’s Pershing Square Holdings and Valeant Pharmaceuticals have agreed to pay $290 million to settle investor claims that they engaged in insider trading in the unsuccessful 2014 takeover bid for Allergan.
Biogen has appointed Jeffrey D. Capello as Executive Vice President and Chief Financial Officer, effective as of December 11, 2017.
Pfizer accused a former global marketing director who quit in January of misappropriating the company’s trade secrets
Dealing a blow to Big Pharma, U.S. Senator Bernie Sanders and other Democrats introduced a bill to allow importation of drugs from Canada, and they demanded President Trump's support
India’s Central Drugs Standard Control Organization (CDSCO) announced (via Twitter) that the Drug Controller General of India has been received of his post and Dr. S. Eswara Reddy will take over as DCGI.
The Philippine Department of Justice said it will indict employees from Sanofi and former and current Philippine health officials over a series of deaths related to the French drugmaker's dengue vaccine.
The Justice Department sued Sage Pharmaceuticals for claims of misbranded drugs.
New program aims to help companies increase productivity with technology solutions for pharmaceutical and chemical sectors
Novartis AG aims to get full ownership of Alcon Inc. through the purchase of a 52% stake in the U.S. eyecare company from Nestlé SA and by buying out minority shareholders, in a deal that will bring the Swiss drug maker much closer to its goal of becoming a global health-care conglomerate.
Before we plunge into 2010, let's take a quick look back at the biotech sector in 2009. It was an okay year, certainly not a great one overall. The Nasdaq Biotechnology Index (NBI) closed 2009 up 16%, rebounding nicely off the March lows but still under-performing the broader indices.
Genzyme Corp said on Monday that Hospira Inc will conduct the final manufacturing process for several of Genzyme's most important drugs. The agreement comes as Genzyme wrestles with manufacturing constraints that have led to shortages of two of its biggest-selling products.
Eli Lilly & Co., like many other pharmaceutical companies, is seeking to make its drug-development efforts more productive as it copes with thin new-product pipelines. Its approach: hiring outside contractors to run tests on its drug candidates.
Biogen Idec Inc. said Monday that CEO James C. Mullen will retire June 8 and the biotechnology company has started a search for his successor.
GlaxoSmithKline is getting into the movie business, pursuing an unusual and most likely controversial strategy to increase interest in a weight-loss drug.
Dan Meyer the current chairman of 3-A recently placed a congratulatory call to Gamajet Cleaning Systems on their latest authorization of the 3-A symbol for their once named, Gamajet IIIA. This rotary impingement tank-cleaning device is the first ever to receive such authorization. Chairman ...
PDA has added a special interest group dedicated to Supply Chain Management and chaired by Genentech's Lucy Cabral.
ISPE, a global not-for-profit association of 24,000 technical professionals working in the manufacturing and drug development sectors of the pharmaceutical industry, has named Anthony Celeste as its North America Regulatory Affairs Advisor, effective immediately. In this role, Mr. Celeste will ...
Five pharmaceutical manufacturing facilities constructed in Singapore, Ireland, and the USA have been selected as Category Winners in the sixth annual Facility of the Year Awards (FOYA) program sponsored by ISPE, INTERPHEX, and Pharmaceutical Processing magazine.
Two five-year manufacturing agreements extend the partnership between the two companies.
The company has now licensed more than 200 generic drugs and is looking less like the Pfizer that many are familiar with.
The initiative is designed to explain agency operations, how it makes decisions, and the drug approval process.
Emerson Process Management and Optimal Industrial Automation Ltd have formed an alliance that integrates Optimals synTQ PAT data management package with Emersons PlantWeb digital plant architecture. The alliance delivers a Process Analytical Technology (PAT) solution that leverages existing ...
Thermo Fisher Scientific Inc. has agreed to buy analytic-instrument maker Ahura Scientific Inc. for $145 million in cash and potentially millions more if certain financial targets are met. The acquisition adds Wilmington, Mass.-based Ahuras lineup of portable chemical-analytical devices which ...